2022 Consensus Statement on the Management of Familial Hypercholesterolemia in Korea

Medicine and Dentistry

• Xanthoma 100%
• Familial Hypercholesterolemia 100%
• Hypolipidemic Agent 50%
• Low Density Lipoprotein Cholesterol 50%
• Statin 50%
• Clinical Feature 50%
• Coronary Artery Disease 50%
• Cardiovascular Risk 50%
• Clinical Finding 50%
• Prematurity 50%
• Ezetimibe 50%
• Conception 50%
• Monogenic Disorder 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Xanthoma 100%
• Familial Hypercholesterolemia 100%
• Monogenic Disorder 50%
• Prematurity 50%
• Cardiovascular Risk 50%
• Clinical Feature 50%
• Low Density Lipoprotein Cholesterol 50%
• Coronary Artery Disease 50%
• Antilipemic Agent 50%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 50%
• Ezetimibe 50%